The Cystic Fibrosis Foundation has awarded funding to Feldan Therapeutics for development of the company’s Feldan Shuttle technology for pulmonary delivery of drugs to treat cystic fibrosis. Neither the company nor the CFF disclosed the amount of the award, which was made under the CFF’s Path to a Cure initiative. Social media posts from the CFF said that the purpose of the funding was “to pursue the development of a technology that could deliver genetic therapies into lung cells in people with cystic fibrosis.”
The Feldan web site describes the Feldan Shuttle as “a short peptide that successfully circumvents endosomal entrapment” that is “engineered to perform highly effective and safe cytoplasmic delivery of multiple types of therapeutics, ranging from small molecules to proteins.”
According to the web site, the company’s development of inhaled CRISPR delivery for the treatment of rare diseases is in the “therapeutic feasibility” stage. The announcement says that the technology “has been demonstrated to enable delivery of various types of functional therapeutic cargos into cultured human airway epithelial cells, a breakthrough in the pulmonary field.”
Feldan CEO François-Thomas Michaud said, “We are very enthusiastic about this support from the Cystic Fibrosis Foundation. We are looking forward to advancing safe delivery of chemical and biological cargos to CF airway epithelia through this grant and taking an active role in offering new therapeutic avenues to CF patients.”
Read the Feldan Therapeutics press release.
Read the CFF tweet:
